News

As per the deal, Aragen is developing CHO cell lines in addition to estimating the characteristics for various antibodies and protein therapeutics. Innovent CEO Michael Yu said Aragen

Ambrx will use site-specific conjugation technology in addition to proprietary linkers and payloads to produce optimized ADCs, which will then be developed and commercialized by Astellas. Agensys site

The solution is used to plan, track and report on clinical trials and is available as a hosted, software-as-a-service (SaaS) application. The Impact CTMS features improved data entry

The approval enables pharma firms that develop pain therapeutics to rely on Frontage for controlled-substance product development support services. Frontage has upgraded its units, security and personnel procedures

The new four-strain vaccine will be marketed as Influsplit Tetra in Germany and Fluarix Tetra in the UK. This is the first four-strain influenza vaccine to be approved

The phase III study is a multi-centre, multi-national study evaluating belimumab. Randomised, double-blind study is designed to asses efficacy and safety profile of belimumab as a combination therapy

As per the designation, the human CD38 monoclonal antibody Daratumumab is suitable for multiple myeloma patients who were administered with three previous therapy lines such as a proteasome

The patent, titled "Methods and Compositions for Oral Administrations of Proteins," covers a core concept of the company’s technology. Oramed CEO Nadav Kidron said, "The Japanese patent approval

The test was aimed at determining the dermal irritation potential of the spray as required by the FDA for biocompatibility. The biocompatibility study, which was conducted on the